Literature DB >> 20203166

The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.

Ajay K Singh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20203166     DOI： 10.2215/CJN.00490110

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  8 in total

1.  Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.

Authors:  Jean-Luc Canon; Johan Vansteenkiste; Michael Hedenus; Pere Gascon; Carsten Bokemeyer; Heinz Ludwig; Jan Vermorken; Jason Legg; Beatriz Pujol; Ken Bridges
Journal:  Med Oncol       Date:  2011-11-13       Impact factor: 3.064

2.  Impact of hemoglobin variability on cardiovascular mortality in maintenance hemodialysis patients.

Authors:  Fu-Jun Lin; Xi Zhang; Lu-Sheng Huang; Gang Ji; Hai-Dong Huang; Yun Xie; Geng-Ru Jiang; Xin Zhou; Wei Lu
Journal:  Int Urol Nephrol       Date:  2018-07-04       Impact factor: 2.370

3.  Low hemoglobin at hemodialysis initiation: an international study of anemia management and mortality in the early dialysis period.

Authors:  Angelo Karaboyas; Hal Morgenstern; Sandra Waechter; Nancy L Fleischer; Raymond Vanholder; Stefan H Jacobson; Manish M Sood; Douglas E Schaubel; Masaaki Inaba; Ronald L Pisoni; Bruce M Robinson
Journal:  Clin Kidney J       Date:  2019-07-05

4.  Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR.

Authors:  Jula K Inrig; Shelly Sapp; Huiman Barnhart; Uptal D Patel; Donal Reddan; Ajay Singh; Robert M Califf; Lynda Szczech
Journal:  Nephrol Dial Transplant       Date:  2012-05-09       Impact factor: 5.992

5.  A threshold trajectory was revealed by isolating the effects of hemoglobin rate of rise in anemia of chronic kidney disease.

Authors:  Gregory Fusco; Ali Hariri; Carlos Vallarino; Ajay Singh; Peter Yu; Lesley Wise
Journal:  Ther Adv Drug Saf       Date:  2017-07-12

6.  A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.

Authors:  Tadao Akizawa; Yusuke Yamaguchi; Tetsuro Otsuka; Michael Reusch
Journal:  Nephron       Date:  2020-06-24       Impact factor: 2.847

7.  The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease.

Authors:  José Portolés; Jose Luis Gorriz; Esther Rubio; Fernando de Alvaro; Florencio García; Vicente Alvarez-Chivas; Pedro Aranda; Alberto Martinez-Castelao
Journal:  BMC Nephrol       Date:  2013-01-07       Impact factor: 2.388

8.  Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Tadao Akizawa; Manabu Iwasaki; Tetsuro Otsuka; Michael Reusch; Toshihiro Misumi
Journal:  Adv Ther       Date:  2019-04-05       Impact factor: 3.845
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.